Lercanidipine Eg

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine EG, is a calcium channel blocker presented as an oral dosage form for systemic use. It is employed to lower elevated blood pressure in adults with hypertension and is prescribed by healthcare professionals as part of a comprehensive antihypertensive regimen.

GNH USA supplies Lercanidipine EG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine EG is a calcium channel blocker indicated for the management of arterial hypertension. It helps achieve sustained blood‑pressure control in several clinical scenarios.

- Essential hypertension: reduces systolic and diastolic pressure to target levels. - Isolated systolic hypertension: lowers elevated systolic readings, especially in older patients. - Secondary hypertension (e.g., renal‑related): contributes to overall blood‑pressure reduction when used with other agents.

Lercanidipine EG may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation often on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but serious cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or airway. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Lercanidipine EG, clinicians should consider several safety aspects.

- Blood pressure monitoring: assess baseline and follow‑up readings. - Renal impairment: adjust therapy if significant kidney dysfunction exists. - Hepatic impairment: use caution in patients with liver disease. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that may raise drug levels. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Elderly patients: start at lower dose and monitor closely. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine EG can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other calcium channel blockers: additive vasodilatory effect leading to excessive hypotension. - Grapefruit juice: can raise drug exposure and risk of adverse events.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect and cause electrolyte shifts. - Beta‑blockers: combined use can produce profound blood‑pressure lowering. - Simvastatin: increased statin levels may raise risk of myopathy.